Press "Enter" to skip to content

Figure 3. The use of thioguanine compounds in patients with inflammatory bowel disease over the years in The Netherlands

Figure 3. The use of thioguanine compounds in patients with inflammatory bowel disease over the years in The Netherlands Figure 3. The use of thioguanine compounds in patients with inflammatory bowel disease over the years in The Netherlands. Number of patients using thioguanine per year, based on data collected from Intercontinental Marketing Services (IMS) and a patient registration that has been maintained since the market introduction of ACES-TG®. Lanvis® is the first market-approved drug in the thioguanine group (for leukemia, in 1975). ACES-TG® was the temporary forerunner of the currently licensed preparation named Thiosix®. All drug compounds are structurally the same.
    Do NOT follow this link or you will be banned from the site!